INTRODUCTION Sodium valproate, or valproic acid (VPA), is a broad-spectrum antiepileptic drug, commonly used for the treatment of epilepsy, bipolar disorder, migraine headache, and diabetic-neuropathy related pain.1 VPA was approved by the U.S. Food and Drug Administration (FDA) in 1978 for treating epilepsy and absence seizures.2 Since then, it has been used either as monotherapy, or in combination with other anticonvulsant agents for the treatment of mixed and complex partial seizures,...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by P. Kaur
Exploiting the Unique Properties of Lanthanide Complexes as FRET Probes: from Quantitation to Protein Dynamics
1 Introduction Fluorescence is the physico-chemical process whereby certain substances, termed fluorophores, are electronically excited by light of a given wavelength and then undergo a transition from an excited singlet state back to the ground state with the emission of light of a longer wavelength. Alternatively, the excited state energy can be transferred, without emission, to a second fluorophore which then emits light of a still longer wavelength.
RETRACTION: Using Electroencephalogram Classification in a Convolutional Neural Network, Infer Privacy on Healthcare Internet of Things 5.0
RETRACTION: U. S. B. K. Mahalaxmi, K. B. Sahay, R. Sabitha, S. L. A. Haleem, P. Kaur, P. Vijayakumar, “ Using Electroencephalogram Classification in a Convolutional Neural Network, Infer Privacy on Healthcare Internet of Things 5.0,” Expert Systems 40, no. 4 (2023): e12942, https://doi.org/10.1111/exsy.12942.
Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients - Papp - 2017 - British Journal of De
ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics. Patients were randomised (1:1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. At Week 16, patients with ?50% improvement from baseline in psoriasis area-and-severity index score (PASI) were eligible to continue to Week 52.
Hair-follicle dermal papilla and sheath fibroblasts provide a supportive microenvironment for human skin regeneration
Previous article in issue: T-type calcium channels as potential biomarkers in melanoma Previous article in issue: T-type calcium channels as potential biomarkers in melanoma
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with P.
Contact P., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack